US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
CN103030617A
(zh)
*
|
2004-03-16 |
2013-04-10 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
US7393836B2
(en)
*
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
WO2006010557A1
(de)
*
|
2004-07-27 |
2006-02-02 |
Boehringer Ingelheim International Gmbh |
D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
EP1828216B1
(en)
*
|
2004-12-16 |
2008-09-10 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
DE602006009772D1
(de)
*
|
2005-02-23 |
2009-11-26 |
Boehringer Ingelheim Int |
Glucopyranosylsubstituierte ((hetero)arylethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters typ 2 (sglt2)
|
WO2006108842A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
AR054871A1
(es)
*
|
2005-07-27 |
2007-07-25 |
Boehringer Ingelheim Int |
Derivados de (hetero)cicloalquiletinil-bencil)-benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, sus uso y proceso para su fabricacion
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CA2620566A1
(en)
*
|
2005-08-30 |
2007-03-08 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
ES2358051T3
(es)
|
2005-09-08 |
2011-05-05 |
Boehringer Ingelheim International Gmbh |
Formas cristalinas de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno, métodos para su preparación y su uso para preparar medicamentos.
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
ES2369016T3
(es)
*
|
2006-02-15 |
2011-11-24 |
Boehringer Ingelheim International Gmbh |
Derivados de benzonitrilo sustituidos por glucopiranosilo, composiciones farmacéuticas que contienen tales tipos de compuestos, su uso y procedimiento para su fabricación.
|
TW200801029A
(en)
|
2006-02-15 |
2008-01-01 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
WO2007136116A2
(en)
*
|
2006-05-19 |
2007-11-29 |
Taisho Pharmaceutical Co., Ltd. |
C-phenyl glycitol compound for the treatment of diabetes
|
WO2007140191A2
(en)
|
2006-05-23 |
2007-12-06 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
EP2054426A1
(en)
|
2006-08-15 |
2009-05-06 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
PT2097102E
(pt)
|
2006-09-07 |
2012-08-03 |
Glaxosmithkline Biolog Sa |
Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
|
WO2008030604A2
(en)
|
2006-09-08 |
2008-03-13 |
Rhode Island Hospital |
Treatment, prevention, and reversal of alcohol-induced brain disease
|
JP5372759B2
(ja)
*
|
2006-09-21 |
2013-12-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル−置換ジフルオロベンジル−ベンゼン誘導体、該化合物を含有する医薬品及びその使用と調製方法
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
WO2008044762A1
(fr)
|
2006-10-13 |
2008-04-17 |
Chugai Seiyaku Kabushiki Kaisha |
Dérivé de spirocétal de thioglucose et utilisation de celui-ci comme agent thérapeutique pour le diabète
|
WO2008049923A1
(en)
*
|
2006-10-27 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
JP2010508371A
(ja)
*
|
2006-11-06 |
2010-03-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法
|
CA2669043A1
(en)
*
|
2006-11-09 |
2008-05-15 |
Boehringer Ingelheim International Gmbh |
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
|
CN101568537A
(zh)
|
2006-12-21 |
2009-10-28 |
安斯泰来制药有限公司 |
C-糖苷衍生物的制造方法及其合成中间体
|
US7795228B2
(en)
*
|
2006-12-28 |
2010-09-14 |
Theracos, Inc. |
Spiroheterocyclic glycosides and methods of use
|
JP2010516742A
(ja)
*
|
2007-01-26 |
2010-05-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
神経変性疾患を予防及び治療する方法
|
WO2008101938A1
(en)
*
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JP2010519273A
(ja)
|
2007-02-21 |
2010-06-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
四置換グルコピラノシル化ベンゼン誘導体、このような化合物を含む薬物、それらの使用及びそれらの製造方法
|
US7846945B2
(en)
*
|
2007-03-08 |
2010-12-07 |
Lexicon Pharmaceuticals, Inc. |
Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
|
ES2466672T3
(es)
|
2007-04-02 |
2014-06-10 |
Theracos, Inc. |
Derivados de glicósido bencílico y métodos de uso
|
PE20090938A1
(es)
*
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
AU2008288770B2
(en)
|
2007-08-23 |
2014-06-12 |
Theracosbio, Llc |
Benzylbenzene derivatives and methods of use
|
PL2200606T3
(pl)
*
|
2007-09-10 |
2018-08-31 |
Janssen Pharmaceutica, N.V. |
Sposób wytwarzania związków użytecznych jako inhibitory SGLT2
|
WO2009068617A1
(en)
*
|
2007-11-30 |
2009-06-04 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
ES2541141T3
(es)
*
|
2008-01-31 |
2015-07-16 |
Astellas Pharma Inc. |
Composición farmacéutica para el tratamiento de las enfermedades del hígado graso
|
UA105362C2
(en)
*
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
BRPI0913129A2
(pt)
|
2008-05-22 |
2016-01-05 |
Bristol Myers Squibb Co |
método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
|
UA104594C2
(en)
|
2008-07-15 |
2014-02-25 |
Теракос, Инк. |
Deuterated benzylbenzole derivatives and using thereof
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
SG193168A1
(en)
*
|
2008-08-22 |
2013-09-30 |
Theracos Inc |
Processes for the preparation of sglt2 inhibitors
|
CN102149717B
(zh)
*
|
2008-08-28 |
2014-05-14 |
辉瑞大药厂 |
二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
|
JP5453431B2
(ja)
|
2008-09-08 |
2014-03-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ピラゾロピリミジン及びcns障害の治療のためのそれらの使用
|
WO2010029089A2
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
AP2011005780A0
(en)
|
2009-02-13 |
2011-08-31 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient.
|
KR20170028452A
(ko)
*
|
2009-02-13 |
2017-03-13 |
베링거 인겔하임 인터내셔날 게엠베하 |
1형 당뇨병, 2형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 sglt2 억제제
|
SG173619A1
(en)
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
ES2460019T3
(es)
*
|
2009-03-31 |
2014-05-13 |
Boehringer Ingelheim International Gmbh |
Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de PDE9A
|
US20110009347A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
PL2451797T3
(pl)
|
2009-07-10 |
2013-08-30 |
Janssen Pharmaceutica Nv |
Proces krystalizacji dla 1-(ß-D-glukopiranozylo)-4-metylo-3-[5-(4-fluorofenylo)-2-tienylometylo]benzenu
|
AR077859A1
(es)
*
|
2009-08-12 |
2011-09-28 |
Boehringer Ingelheim Int |
Compuestos para el tratamiento de trastornos del snc
|
MX2012003126A
(es)
|
2009-09-21 |
2012-06-19 |
Gilead Sciences Inc |
Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
|
CA2775961C
(en)
|
2009-09-30 |
2017-11-07 |
Boehringer Ingelheim International Gmbh |
Method for the preparation of a crystalline form of 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
HRP20150945T1
(hr)
|
2009-09-30 |
2015-10-09 |
Boehringer Ingelheim International Gmbh |
Postupci za proizvodnju derivata benzil-benzena supstituiranog glukopiranozilom
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
BR112012008939B1
(pt)
*
|
2009-10-14 |
2021-06-22 |
Janssen Pharmaceutica Nv |
Processo para a preparação de compostos úteis como inibidores de sglt2
|
JP5696156B2
(ja)
|
2009-11-02 |
2015-04-08 |
ファイザー・インク |
ジオキサ−ビシクロ[3.2.1]オクタン−2,3,4−トリオール誘導体
|
AU2010323068B2
(en)
|
2009-11-27 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
|
EP2368552A1
(en)
|
2010-03-25 |
2011-09-28 |
Boehringer Ingelheim Vetmedica GmbH |
1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
|
US20140088027A1
(en)
*
|
2010-03-30 |
2014-03-27 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
MX2012011631A
(es)
|
2010-04-06 |
2013-01-18 |
Arena Pharm Inc |
Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
|
JP6034781B2
(ja)
|
2010-05-05 |
2016-11-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
併用療法
|
KR101931209B1
(ko)
|
2010-05-11 |
2018-12-20 |
얀센 파마슈티카 엔.브이. |
Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
PH12012502524A1
(en)
|
2010-06-24 |
2014-02-10 |
Boehringer Ingelheim Int |
Diabetes therapy
|
AP3269A
(en)
|
2010-07-22 |
2015-05-31 |
Gilead Sciences Inc |
Methods and compounds for treating paramyxoviridaevirus infections
|
DK2603511T3
(en)
|
2010-08-12 |
2017-05-08 |
Boehringer Ingelheim Int |
6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO- [3,4-D] PYRIMIDIN-4-ON DERIVATIVES AND THEIR USES AS PDE9A INHIBITORS
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
JP5941916B2
(ja)
|
2010-09-22 |
2016-06-29 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
CN102453026A
(zh)
*
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
AU2011325286B2
(en)
|
2010-11-02 |
2015-04-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical combinations for the treatment of metabolic disorders
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
JP6105489B2
(ja)
*
|
2011-02-18 |
2017-03-29 |
シャンハイ インリ ファーマシューティカル カンパニー リミティド |
アリールグルコシド化合物、その調製方法及び使用
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
WO2012135570A1
(en)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
RS55056B1
(sr)
|
2011-04-13 |
2016-12-30 |
Janssen Pharmaceutica Nv |
Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
(2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
|
CA2837627A1
(en)
|
2011-06-03 |
2012-12-06 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
JP5875678B2
(ja)
*
|
2011-06-25 |
2016-03-02 |
山東軒竹医薬科技有限公司 |
C−グルコシド誘導体
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
HUE061596T2
(hu)
|
2011-07-15 |
2023-07-28 |
Boehringer Ingelheim Int |
Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
RU2517091C2
(ru)
*
|
2012-02-20 |
2014-05-27 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации) |
Средство, обладающее мочегонным действием
|
RU2500407C2
(ru)
*
|
2012-02-20 |
2013-12-10 |
Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации |
Средство, обладающее мочегонным действием
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
IN2014DN08582A
(en, 2012)
|
2012-05-09 |
2015-05-22 |
Boehringer Ingelheim Int |
|
JP6218811B2
(ja)
|
2012-05-14 |
2017-10-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sirs及び/又は敗血症の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
US9145434B2
(en)
*
|
2012-07-26 |
2015-09-29 |
Boehringer Ingelheim International Gmbh |
Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
CN103864737B
(zh)
*
|
2012-12-17 |
2016-08-17 |
天津药物研究院 |
含脱氧葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
ES2969245T3
(es)
|
2013-03-14 |
2024-05-17 |
Msd Int Gmbh |
Formas cristalinas y métodos para preparar inhibidores de SGLT2
|
PT2981269T
(pt)
|
2013-04-04 |
2023-10-10 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamento de distúrbios metabólicos em animais equinos
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
HK1213818A1
(zh)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
RS63042B1
(sr)
|
2013-04-18 |
2022-04-29 |
Boehringer Ingelheim Int |
Farmaceutske kompozicije, metode lečenja i njihova upotreba
|
CN104250272B
(zh)
*
|
2013-06-27 |
2018-10-09 |
上海方楠生物科技有限公司 |
一种利用微反应器制备列净类药物中间体的方法
|
CN105611920B
(zh)
*
|
2013-10-12 |
2021-07-16 |
泰拉科斯萨普有限责任公司 |
羟基-二苯甲烷衍生物的制备
|
US20160280619A1
(en)
*
|
2013-10-31 |
2016-09-29 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
|
BR112016011564B1
(pt)
|
2013-12-17 |
2021-02-09 |
Boehringer Ingelheim Vetmedica Gmbh |
usos de inibidores de sglt2 ou formas farmaceuticamente aceitáveis dos mesmos para o tratamento de distúrbios metabólicos em animais felinos
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
CN106349201B
(zh)
*
|
2014-01-03 |
2018-09-18 |
山东轩竹医药科技有限公司 |
光学纯的苄基-4-氯苯基的c-糖苷衍生物
|
ES2593050T3
(es)
|
2014-01-03 |
2016-12-05 |
Xuanzhu Pharma Co., Ltd. |
Derivados bencil-4-clorofenil-C-glucósidos ópticamente puros como inhibidores del SGLT (diabetes mellitus)
|
CN103739581B
(zh)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-芳基葡萄糖苷sglt2抑制剂
|
FI3485890T3
(fi)
*
|
2014-01-23 |
2023-07-18 |
Boehringer Ingelheim Vetmedica Gmbh |
SGLT2-estäjät aineenvaihduntahäiriöiden hoitoon koiraeläimillä
|
CN104861002A
(zh)
*
|
2014-02-26 |
2015-08-26 |
天津药物研究院 |
含3,6-脱水葡萄糖结构的苯基c-葡萄糖苷衍生物及其制备方法和用途
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
PT3125882T
(pt)
|
2014-04-01 |
2020-08-17 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamento de distúrbios metabólicos em animais equinos
|
CN105001213B
(zh)
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
DK3197429T3
(da)
|
2014-09-25 |
2024-08-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
|
TWI740546B
(zh)
|
2014-10-29 |
2021-09-21 |
美商基利科學股份有限公司 |
製備核糖苷的方法
|
DE102014018230B4
(de)
*
|
2014-12-04 |
2016-10-27 |
Mann + Hummel Gmbh |
Akkumulator-Anordnung für ein Fahrzeug
|
EP3256482B1
(en)
*
|
2015-02-09 |
2019-11-27 |
Indoco Remedies Limited |
Process for the preparation of sglt inhibitor compounds
|
CZ2015110A3
(cs)
|
2015-02-18 |
2016-08-31 |
Zentiva, K.S. |
Pevné formy empagliflozinu
|
JP2018507914A
(ja)
|
2015-03-09 |
2018-03-22 |
インテクリン・セラピューティクス・インコーポレイテッド |
非アルコール性脂肪肝疾患および/またはリポジストロフィーの処置のための方法
|
CZ2015279A3
(cs)
|
2015-04-24 |
2016-11-02 |
Zentiva, K.S. |
Pevné formy amorfního empagliflozinu
|
CN106336403A
(zh)
*
|
2015-07-14 |
2017-01-18 |
江苏豪森药业集团有限公司 |
依帕列净的工业制备方法
|
BR112018003749B1
(pt)
|
2015-08-27 |
2023-10-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Composições farmacêuticas líquidas compreendendo inibidores sglt-2, kit de peças e processo para a produção da composição farmacêutica líquida
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
EP3349762B1
(en)
|
2015-09-15 |
2021-08-25 |
Laurus Labs Limited |
Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
|
HK1257628A1
(zh)
|
2015-09-16 |
2019-10-25 |
Gilead Sciences, Inc. |
治療沙粒病毒科和冠狀病毒科病毒感染的方法
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
RU2614142C1
(ru)
*
|
2016-01-14 |
2017-03-23 |
Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" |
Способ получения мета-хлорбензгидриламина - полупродукта в синтезе противосудорожного препарата галодиф
|
US10913762B2
(en)
*
|
2016-01-27 |
2021-02-09 |
Msn Laboratories Private Limited |
Process for the preparation of D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl] oxy]phenyl] methyl] phenyl]-, (1S) and its crystalline forms thereof
|
WO2017141202A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Lupin Limited |
Complex of sglt2 inhibitor and process for preparation thereof
|
US10155000B2
(en)
|
2016-06-10 |
2018-12-18 |
Boehringer Ingelheim International Gmbh |
Medical use of pharmaceutical combination or composition
|
CN107641139A
(zh)
*
|
2016-07-22 |
2018-01-30 |
江苏豪森药业集团有限公司 |
达格列净中间体的晶型及其制备方法
|
HRP20211154T1
(hr)
|
2016-10-13 |
2021-10-15 |
Boehringer Ingelheim International Gmbh |
Postupak za pripravu derivata benzil-benzena supstituiranih glukopiranozilom
|
EA201990951A1
(ru)
|
2016-10-19 |
2019-11-29 |
|
Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
|
US20180125813A1
(en)
|
2016-11-10 |
2018-05-10 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CN108285439B
(zh)
*
|
2017-01-09 |
2023-05-02 |
江苏天士力帝益药业有限公司 |
一种碳糖苷类钠葡萄糖转运蛋白体2抑制剂
|
WO2018163194A1
(en)
*
|
2017-03-10 |
2018-09-13 |
Msn Laboratories Private Limited, R&D Center |
A process for the preparation of d-glucitol, 1,5-anhydro-1-c-[4-chloro-3-[[4- [[(3s)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, ( 1 s)
|
CA3056072C
(en)
|
2017-03-14 |
2022-08-23 |
Gilead Sciences, Inc. |
Methods of treating feline coronavirus infections
|
CN110996951A
(zh)
|
2017-04-03 |
2020-04-10 |
科赫罗斯生物科学股份有限公司 |
治疗进行性核上性麻痹的PPARγ激动剂
|
WO2018204198A1
(en)
|
2017-05-01 |
2018-11-08 |
Gilead Sciences, Inc. |
Crystalline forms of (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
|
WO2018207113A1
(en)
|
2017-05-09 |
2018-11-15 |
Piramal Enterprises Limited |
A process for the preparation of sglt2 inhibitor and intermediates thereof
|
US11046676B2
(en)
|
2017-06-05 |
2021-06-29 |
Laurus Labs Limited |
Process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof
|
CN107163092B
(zh)
*
|
2017-06-13 |
2020-05-19 |
杭州科巢生物科技有限公司 |
Sglt-2糖尿病抑制剂及其中间体的制备方法
|
JP7174757B2
(ja)
*
|
2017-07-04 |
2022-11-17 |
イントゥーセル,インコーポレーティッド |
切断可能なリンカーを含む化合物及びその使用
|
ES3000461T3
(en)
|
2017-07-11 |
2025-02-28 |
Gilead Sciences Inc |
Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
|
MA51203A
(fr)
|
2017-11-30 |
2020-10-07 |
Idorsia Pharmaceuticals Ltd |
Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
|
EP3762379A1
(en)
|
2018-03-07 |
2021-01-13 |
Bayer Aktiengesellschaft |
Identification and use of erk5 inhibitors
|
US20210113561A1
(en)
|
2018-04-17 |
2021-04-22 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CZ2018188A3
(cs)
|
2018-04-18 |
2019-10-30 |
Zentiva, K.S. |
Částice s obsahem amorfního empagliflozinu, způsob jejich přípravy a farmaceutický přípravek
|
CN108610385A
(zh)
*
|
2018-04-23 |
2018-10-02 |
中国科学院成都生物研究所 |
一种钠-葡萄糖协同转运蛋白1抑制剂的药物用途
|
CN110117300A
(zh)
*
|
2018-04-23 |
2019-08-13 |
中国科学院成都生物研究所 |
包含钠-葡萄糖协同转运蛋白1抑制剂的药物用途
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
CN108774275A
(zh)
*
|
2018-07-16 |
2018-11-09 |
西北大学 |
一步合成全乙酰基-α-O-苄基糖的方法
|
CA3105626A1
(en)
|
2018-07-19 |
2020-01-23 |
Astrazeneca Ab |
Methods of treating hfpef employing dapagliflozin and compositions comprising the same
|
JP2021532191A
(ja)
|
2018-07-25 |
2021-11-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アルポート症候群の治療に使用するためのエンパグリフロジン
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
JPWO2020050361A1
(ja)
*
|
2018-09-06 |
2021-08-30 |
株式会社トクヤマ |
β−C−アリールグリコシド誘導体の製造方法
|
WO2020084560A1
(en)
*
|
2018-10-26 |
2020-04-30 |
Janssen Pharmaceutica Nv |
Glucopyranose derivatives useful as sglt2 inhibitors
|
PH12021550901A1
(en)
|
2018-10-29 |
2022-03-21 |
Boehringer Ingelheim Int |
Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
|
JP7425793B2
(ja)
|
2018-10-29 |
2024-01-31 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
|
WO2020242253A1
(ko)
*
|
2019-05-30 |
2020-12-03 |
동아에스티 주식회사 |
Sglt-2 억제제인 신규 엠파글리플로진 유도체
|
CN112047915B
(zh)
*
|
2019-06-05 |
2023-02-17 |
北京惠之衡生物科技有限公司 |
C-糖苷类衍生物新的制备工艺
|
US20220324897A1
(en)
*
|
2019-07-05 |
2022-10-13 |
Shandong Danhong Pharmaceutical Co., Ltd. |
Crystal form of sglt inhibitor and application thereof
|
CN114585358B
(zh)
*
|
2019-07-26 |
2023-11-10 |
东宝紫星(杭州)生物医药有限公司 |
一种SGLTs/DPP4抑制剂及其应用
|
CA3158368A1
(en)
|
2019-11-28 |
2021-06-03 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors in the drying-off of non-human mammals
|
EP4076402A1
(en)
|
2019-12-19 |
2022-10-26 |
KRKA, d.d., Novo mesto |
Dosage form comprising amorphous solid solution of empagliflozin with polymer
|
KR102111248B1
(ko)
|
2019-12-30 |
2020-05-14 |
유니셀랩 주식회사 |
새로운 엠파글리플로진의 공결정
|
EP4096678A1
(en)
|
2020-01-27 |
2022-12-07 |
Gilead Sciences, Inc. |
Methods for treating sars cov-2 infections
|
MX2022010090A
(es)
|
2020-02-17 |
2022-09-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
|
CA3173808A1
(en)
|
2020-03-06 |
2021-09-10 |
Vertex Pharmaceuticals Incorporated |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
TWI785528B
(zh)
|
2020-03-12 |
2022-12-01 |
美商基利科學股份有限公司 |
1’-氰基核苷之製備方法
|
KR102207319B1
(ko)
|
2020-03-23 |
2021-01-25 |
유니셀랩 주식회사 |
새로운 엠파글리플로진의 공결정
|
US11701372B2
(en)
|
2020-04-06 |
2023-07-18 |
Gilead Sciences, Inc. |
Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
|
KR102150825B1
(ko)
|
2020-04-06 |
2020-09-03 |
유니셀랩 주식회사 |
새로운 sglt-2 억제제의 신규한 공결정
|
JP2023520899A
(ja)
|
2020-04-07 |
2023-05-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
頭痛障害の処置のための方法
|
JP2023523596A
(ja)
|
2020-04-22 |
2023-06-06 |
バイエル アクチェンゲゼルシャフト |
心血管疾患および/または腎疾患を治療および/または予防するためのフィネレノンとsglt2阻害剤の組み合わせ
|
US11975012B2
(en)
|
2020-05-29 |
2024-05-07 |
Gilead Sciences, Inc. |
Remdesivir treatment methods
|
WO2021250565A1
(en)
*
|
2020-06-10 |
2021-12-16 |
Hikal Limited |
An improved process for preparation of empagliflozin and its crystalline polymorph
|
KR20230028486A
(ko)
|
2020-06-24 |
2023-02-28 |
길리애드 사이언시즈, 인코포레이티드 |
1'-시아노 뉴클레오시드 유사체 및 이의 용도
|
US11786540B2
(en)
*
|
2020-07-10 |
2023-10-17 |
Rosalind Franklin University Of Medicine And Science |
Gliflozins and a method for their delivery during resuscitation from cardiac arrest to improve survival outcomes
|
WO2022022865A1
(en)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
FI4204421T3
(fi)
|
2020-08-27 |
2024-06-25 |
Gilead Sciences Inc |
Koostumuksia ja menetelmiä virusinfektioiden hoitoon
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
KR20220068805A
(ko)
|
2020-11-19 |
2022-05-26 |
한미약품 주식회사 |
신규한 글루코스 유도체
|
EP4023644A1
(en)
|
2020-12-30 |
2022-07-06 |
Zaklady Farmaceutyczne Polpharma SA |
Process for the preparation of a pharmaceutical agent
|
WO2022160737A1
(zh)
*
|
2021-01-26 |
2022-08-04 |
东宝紫星(杭州)生物医药有限公司 |
四氢吡喃环类化合物的晶型及其制备方法
|
EP4315350A1
(en)
|
2021-04-01 |
2024-02-07 |
AstraZeneca UK Limited |
Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
|
CN117715640A
(zh)
|
2021-07-28 |
2024-03-15 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物,特别是犬科动物中预防和/或治疗心脏疾病的用途
|
WO2023006747A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
CN113773194B
(zh)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
|
US20250170128A1
(en)
|
2021-12-30 |
2025-05-29 |
NEWAMSTERDAM PHARMA B.V. (Dutch Chamber of Commerce No. 5597 1946) |
Obicetrapib and SGLT2 Inhibitor Combination
|
EP4469038A1
(en)
|
2022-01-26 |
2024-12-04 |
Astrazeneca AB |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|
US20230295172A1
(en)
|
2022-03-02 |
2023-09-21 |
Gilead Sciences, Inc. |
Compounds and methods for treatment of viral infections
|
WO2023213715A1
(en)
|
2022-05-04 |
2023-11-09 |
Société des Produits Nestlé S.A. |
Ampk activator (cbda) and sglt2 inhibitor for metabolic health
|
EP4524138A4
(en)
|
2022-05-12 |
2025-09-03 |
Zhejiang Huahai Pharm Co Ltd |
PROCESS FOR THE PREPARATION OF A GLUCOPYRANOSYL-CONTAINING COMPOUND
|
WO2023227492A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
WO2024033287A1
(en)
|
2022-08-12 |
2024-02-15 |
Société des Produits Nestlé S.A. |
Hydroxycholest-5-ene glycosides as inhibitors of sglt2
|
WO2024033288A1
(en)
|
2022-08-12 |
2024-02-15 |
Société des Produits Nestlé S.A. |
Salicin derivatives as inhibitors of sglt2
|
CN119654142A
(zh)
|
2022-08-18 |
2025-03-18 |
雀巢产品有限公司 |
作为sglt2的抑制剂的甲基化根皮素类似物
|
WO2024056498A1
(en)
|
2022-09-12 |
2024-03-21 |
Société des Produits Nestlé S.A. |
Oxindole alkaloid derivatives as inhibitors of sglt2
|
WO2024068511A1
(en)
|
2022-09-28 |
2024-04-04 |
Société des Produits Nestlé S.A. |
Diterpenoid derivatives as inhibitors of sglt2
|
EP4378455A1
(en)
|
2022-11-29 |
2024-06-05 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A pharmaceutical formulation comprising empagliflozin
|
CN115772163B
(zh)
*
|
2022-12-09 |
2025-07-22 |
中国科学院成都生物研究所 |
吲哚糖苷类化合物及吡咯糖苷类化合物及合成方法与应用
|
EP4420658A1
(en)
|
2023-02-24 |
2024-08-28 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising empagliflozin
|
US20240307628A1
(en)
|
2023-03-06 |
2024-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
EP4442254A1
(en)
|
2023-04-04 |
2024-10-09 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Film coated tablets comprising empagliflozin
|
EP4442252A1
(en)
|
2023-04-04 |
2024-10-09 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A tablet formulation of a solid dispersion comprising empagliflozin
|
EP4442253A1
(en)
|
2023-04-04 |
2024-10-09 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising empagliflozin and surfactant
|
TW202446389A
(zh)
|
2023-04-24 |
2024-12-01 |
荷蘭商新阿姆斯特丹製藥公司 |
非晶形奧比特拉(obicetrapib)與sglt2抑制劑之組合
|
US20240390332A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
|
TW202508593A
(zh)
|
2023-05-24 |
2025-03-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
|
KR20250007816A
(ko)
|
2023-07-06 |
2025-01-14 |
주식회사 경보제약 |
엠파글리플로진 2l프롤린의 신규 결정형 및 이의 제조방법
|
WO2025125513A1
(en)
|
2023-12-15 |
2025-06-19 |
AstraZeneca Ireland Limited |
Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension
|
US12357577B1
(en)
|
2024-02-02 |
2025-07-15 |
Gilead Sciences, Inc. |
Pharmaceutical formulations and uses thereof
|